{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-029393","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.227372+00:00","generated_at":"2026-06-11T10:57:18.432633+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Avalo extends loan forbearance to Sept 15, receives Apollo license breach notice for $837K","bullets":["Second forbearance agreement extends forbearance period to September 15, 2023; company must maintain at least $3M cash in deposit accounts subject to control agreement.","Company acknowledges MAC default and outstanding loan principal of $13,743,373 plus interest and fees.","Apollo AP43 Limited alleges breach of license agreement due to $837,522 owed to service provider; dispute resolution initiated.","Preliminary cash and cash equivalents approximately $5.4M as of August 11, 2023; subject to change.","Company may need to negotiate settlement with Apollo, but success not guaranteed."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-029393","json":"https://secwatch.observer/filing/0001628280-23-029393.json","markdown":"https://secwatch.observer/filing/0001628280-23-029393.md","text":"https://secwatch.observer/filing/0001628280-23-029393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023029393/0001628280-23-029393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023029393/avtx-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:57:18.432633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2801b487acf3a3b2c04f32b4e7164d026d6833ce","claim":"Avalo Therapeutics, Inc. entered into Second Forbearance Agreement with Holders valued at forbearance period extended to September 15, 2023; cash deposit set at $3,000,000 without addition o (effective 2023-08-14).","evidence_excerpt":"On August 14, 2023, the Company and the Holders entered into a Second Forbearance Agreement (the “Second Forbearance Agreement”) whereby the forbearance period was extended to September 15, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023029393/0001628280-23-029393-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Holders"},{"label":"Value","value":"forbearance period extended to September 15, 2023; cash deposit set at $3,000,000 without addition o"},{"label":"Effective","value":"2023-08-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}